QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Biological: Avelumab;   Biological: Bevacizumab;   Drug: Capecitabine;   Biological: Cetuximab;   Drug: Cisplatin;   Drug: cyclophosphamide;   Drug: 5-Fluorouracil (5-FU);   Drug: fulvestrant;   Drug: leucovorin;   Drug: nab-paclitaxel;   Biological: nivolumab;   Drug: Lovaza;   Radiation: Stereotactic Body Radiation Therapy;   Biological: ALT-803;   Biological: ETBX-011;   Biological: ETBX-021;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6207;   Biological: GI-6301;   Biological: haNK
Sponsor:   NantCell, Inc.
Not yet recruiting - verified May 2017

http://ift.tt/2siFSLY